PMC:7195088 / 31064-31583
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T34 | 92-100 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T35 | 155-157 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
| T36 | 171-173 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
| T37 | 271-279 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T24 | 506-511 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T161 | 321-329 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T162 | 412-420 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T172 | 66-75 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | Humanized |
| T173 | 128-136 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
| T174 | 293-296 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T175 | 427-432 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T418 | 102-113 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T419 | 155-157 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T421 | 171-173 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T423 | 362-373 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T424 | 427-432 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T243 | 2-53 | Sentence | denotes | Primary endpoint: ICU admission (follow-up 29 days) |
| T244 | 54-170 | Sentence | denotes | Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. |
| T245 | 171-421 | Sentence | denotes | IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. |
| T246 | 422-471 | Sentence | denotes | Open-label RCT (NCT04331808, not yet recruiting). |